Denali Therapeutics reports Q1 EPS (68c), consensus (70c)

Reports in Q1 there was no collaboration revenue for the quarter ended March 31 , compared to $35.1M for the quarter ended March 31, 2023. The decrease in collaboration revenue was primarily due to decreases in revenue earned under the Sanofi (SNY)Collaboration and Takeda (TAK) Collaboration of $25M and $10.M respectively. “It has been an impactful first quarter, and we are excited about multiple opportunities to accelerate and expand our portfolio. We presented new positive two-year clinical data on tividenofusp alfa in MPS II at WORLDSymposiumTM, and we are encouraged by recent interactions with the FDA about the potential path to patients,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. “We also initiated the first clinical trial with our second enzyme replacement therapy, DNL126, for children with MPS IIIA, and we achieved an important milestone with our eIF2B agonist program, DNL343, completing enrollment in the Phase 2/3 HEALEY ALS Platform Trial. With a focus on our Transport Vehicle platform and additional capital raised, we are well positioned to lead in the promising field of BBB-crossing therapeutics for people living with neurodegenerative and lysosomal storage diseases.”